№ lp_1_2_63795
File format: docx Character count: 27243 File size: 125 KB
This document is a clinical pathway template developed for prescribing acetylcholinesterase inhibitors and memantine in the treatment of dementia, particularly Alzheimer’s disease, Parkinson’s disease dementia, and Dementia with Lewy bodies.
Year: 2018
Region / city: London
Theme: Dementia care, pharmacology
Document type: Clinical guideline
Organization / institution: London Dementia Clinical Network (NHS England and Improvement London Region)
Author: Delia Bishara (Consultant Pharmacist, South London and Maudsley NHS Foundation Trust)
Target audience: Healthcare professionals involved in dementia care
Effective period: 2018–present
Approval date: Not specified
Date of amendments: Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
SmartPA Criteria Proposal Drug/Drug Class: Alzheimer’s Agents, Acetylcholinesterase Inhibitors, N-Methyl-D-Aspartate Receptor Antagonists & Combinations PDL Edit
Year: 2026
Region / city: Missouri
Document Type: Proposal
Organization: MO HealthNet
Author: MO HealthNet, Conduent
Target Audience: MO HealthNet participants, healthcare providers
Period of validity: Ongoing
Approval Date: January 20, 2026
Revision Date: May 21, 2008
Criteria Status: Revision of Existing Criteria
Integrated Medication Guidelines for the use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia
Note: Year
Topic: Medication Guidelines for Dementia Treatment
Document Type: Clinical Guideline
Organization / Institution: South East London CCGs
Target Audience: Healthcare professionals involved in dementia treatment
Context: This clinical guideline outlines the prescribed use of Donepezil, Galantamine, Rivastigmine, and Memantine for the treatment of dementia, developed for healthcare providers in South East London.
Topics: Lewy acetylcholinesterase donepezil